RE:RE:RE:RE:RE:RE:Something I just seen !They coudn't market it for Parkinson's based on one trial. They would need the indication from Health Canada/FDA which no one has to date and likely would not happen without a lot more robust RCTs. It would just be indirect marketing related to a published study so unlikely this would signfiicantly increase sales IMO